Our collective purpose is to improve the lives of patients with brain tumors
MATTHEW E. LIKENS
President and Chief Executive Officer
Mr Likens is an accomplished leader in the medical device industry. Prior to coming to GT Medical Technologies, he served as the president and chief executive officer of Ulthera, Inc. There, he led the startup from pre-commercialization to more than $100M in revenue and a $600M acquisition by Merz Pharma GmbH.
Mr Likens’ professional career began with Johnson & Johnson. However, he spent the bulk of his career at Baxter Healthcare Corporation, where he progressed through a variety of domestic and international sales, marketing, and general management roles that ultimately culminated in the position of president of Baxter Biotech North America, and then the president of its US Renal Care division. After departing Merz in mid-2016, Mr Likens joined the board of Luma Therapeutics, a startup with a novel approach for the treatment of psoriasis, and CHF Solutions, a NASDAQ-listed company focused on supporting patients suffering from congestive heart failure due to fluid overload.
Mr Likens is a member of the Greater Phoenix Economic Council Healthcare Innovation Committee and the City of Mesa Economic Development Advisory Board, as well as a member of the Kent State University College of Business Advisory Board. He joined GT Medical Technologies because he was inspired by the company’s powerful purpose of “Improving the lives of patients with brain tumors.”
DAVID BRACHMAN, MD, FASTRO
Chief Technology Officer
Dr Brachman was instrumental in the development of GammaTile Therapy. He is a cofounder and the chief technology officer of GT Medical Technologies, as well as an inventor on all of the company’s product patents. A nationally recognized radiation oncologist and researcher and the author of more than 50 peer-reviewed publications. His publishing credits include The Lancet, Cancer Research, and The New England Journal of Medicine. Dr Brachman is renowned for his extensive neuro-oncology clinical expertise.
Dr Brachman recently retired from practice after more than 15 years as the chairman and medical director of the Radiation Oncology department and codirector of the GammaKnife program at St. Joseph’s Hospital and Medical Center and Barrow Neurological Institute in Phoenix, Arizona. His considerable radiation oncology background includes a position as the professor of Radiation Oncology at the University of Arizona College of Medicine – Phoenix, and more than 15 years as a member of the NCI-sponsored Radiation Therapy Oncology Group CNS Tumor Steering Committee.
BRIAN MARTIN, MBA
Vice President of Strategy and Corporate Development
Prior to joining GT Medical Technologies, Mr Martin held positions in business development at several startups, investment roles at a venture capital firm and life sciences incubator, and roles in marketing at a Fortune 500 medical device company. This diverse experience informs Mr Martin’s decision-making across the organization and his leadership in strategic partnering, finance, and investor relations. His focus is on bringing analytical frameworks to strategic decision-making in medtech and capital allocation.
Vice President of Operations
Mr Lopez is a results-driven engineering leader with extensive experience in operations and manufacturing management within the medical device industry, including Boston Scientific Corp, Polaris Medical Inc, and Ulthera, Inc. He has a proven track record of leading strategic project planning and execution, and of enhancing operational efficiency and profitability. As a Lean Six Sigma Black Belt, he brings demonstrated expertise in the implementation of cutting-edge production methodologies with specialization in lean manufacturing processes. He is also highly skilled in bridging the gap between business objectives and supply chain capabilities.
Vice President of Operations
Mr Lopez is a results-driven engineering leader with extensive experience in operations and manufacturing management within the medical device industry, including Boston Scientific Corporation, Polaris Medical Inc. and Ulthera, Inc. He has a proven track record of leading strategic project planning and execution, and of enhancing operational efficiency and profitability. As a Lean Six Sigma Black Belt, he brings demonstrated expertise in the implementation of cutting-edge production methodologies with specialization in lean manufacturing processes. He is also highly skilled in bridging the gap between business objectives and supply chain capabilities.
Vice President of Sales and Marketing
Mr Bushnell is a medical device executive and commercial leader with 25 years of experience in developing and managing both sales and marketing teams in emerging and highly competitive global medical device markets. Over his 18 years at Ethicon Endo-Surgery/Johnson & Johnson, Mr Bushnell held positions of increasing responsibility and influence, as the director of Sales and Marketing, and as the director of Market Development. More recently, he was the vice president of Sales at Ulthera, Inc. from its inception as a startup company to its acquisition. For GT Medical Technologies, he contributes strong general management acumen, compliance expertise, and extensive knowledge of the medical industry and its network of thought leaders.
LISA MISELL, PhD
Vice President of Clinical Affairs
An accomplished medical device executive, Dr Misell has more than 20 years of clinical research experience spanning several therapeutic areas, including oncology, infertility, diabetes, metabolic disorders, neurology, exercise physiology, rheumatology, and dermatology. Dr Misell earned her doctoral degree in Metabolic Biochemistry from the University of California, Berkeley. In addition to fulfilling the role as a principal investigator during her time in academia, Dr Misell has directed studies across all phases of development from pilot to postapproval and registry studies.
Prior to joining GT Medical Technologies, Dr Misell was the vice president of Clinical and Medical Affairs at Dyve Biosciences. While there, she ran the clinical department, which executed more than 20 proof-of-concept trials and a phase 2 rheumatology trial with 20 clinical sites across the US. Prior to joining Dyve, she was the vice president of Clinical Affairs at Ulthera, Inc., where she built the Clinical Affairs department and ran more than 50 clinical studies. She has held similar roles at Suneva Medical, KineMed, and Allergan. At Allergan, she was responsible for managing more than 45 investigator-initiated studies, multisite comparator trials, and a registry study that enrolled more than 1000 subjects across more than 20 sites. For GT Medical Technologies, Dr Misell contributes expertise in developing clinical programs and registries for existing and pipeline products.